Phage antibodies to radiation-inducible neoantigens

Details Phage antibodies to radiation-inducible neoantigens Phage antibodies to radiation-inducible neoantigens

2007-12-11

2007-12-11

Ketter, James (Department: 1636)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S235100, C435S006120

Reexamination Certificate

active

10689006

ABSTRACT:
A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. The method includes the steps of: (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are therapeutic and diagnostic methods using targeting ligands that bind an irradiated tumor.

REFERENCES:
patent: 4515165 (1985-05-01), Carroll
patent: 4619823 (1986-10-01), Yokoyama et al.
patent: 4670386 (1987-06-01), Sugaar
patent: 5093104 (1992-03-01), Kaminsky
patent: 5292524 (1994-03-01), Male et al.
patent: 5328840 (1994-07-01), Coller
patent: 5334369 (1994-08-01), Halushka et al.
patent: 5382680 (1995-01-01), Abraham et al.
patent: 5516881 (1996-05-01), Lee et al.
patent: 5693627 (1997-12-01), Schieven
patent: 5759542 (1998-06-01), Gurewich
patent: 2003/0130190 (2003-07-01), Hallahan et al.
patent: 2621311 (1976-11-01), None
patent: 229718 (1987-01-01), None
patent: WO8605693 (1986-10-01), None
patent: WO9306835 (1993-04-01), None
patent: WO93/14791 (1993-08-01), None
patent: WO9320229 (1993-10-01), None
patent: WO9533496 (1995-12-01), None
patent: WO9625947 (1996-08-01), None
International Preliminary Examination Report for corresponding PCT Appl. No. PCT/US04/34719 dated Oct. 12, 2005.
U.S. Appl. No. 10/259,086, filed Jul. 10, 2003, Hallahan et al.
International Search Report for corresponding PCT Appl. No. PCT/US04/34719 dated Jan. 26, 2005.
Arap et al., Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model,Science279:377-380 (Jan. 16, 1998).
Bird et al., Single-Chain Antigen-Binding Proteins,Science242:423-426 (Oct. 21, 1988).
Edmonds, Antibody-Targeted Chemotherapy with Mylotarg Shows Promise for Many Adults with Deadly Form of Leukemia,American Society of Clinical Oncology Meeting in New Orleans(May 21, 2000).
Ellerby et al, Anti-cancer activity of targeted pro-apoptotic peptides,Nature Medicine5(9):1032-1038 (Sep. 1999).
Fox and Harris, Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy,Investigational New Drugs15:15-28 (1997).
Hallahan et al., Spatial and temporal control of gene therapy using ionizing radiation,Nat Med. 1(8):786-791 (Aug. 1995) (ABSTRACT).
Hallahan, Radiation-Mediated Gene Expression in the Pathogenesis of the Clinical Radiation Response,Semin Radiat Oncol. 6(4):250-267 (Oct. 1996) (ABSTRACT).
Hallahan et al., Radiation-Mediated Control of Drug Delivery,Am J. Clin Onocol. 24(5):473-480 (Oct. 2001) (ABSTRACT).
Hallahan et al., X-ray-induced P-selectin localization to the lumen of tumor blood vessels,Cancer Res. 58(2):5216-5220 (Nov. 15, 1998) (ABSTRACT).
Hellstr{hacek over (o)}m et al., Immunoconjugates and immunotoxins for therapy of solid tumors,Cancer Chemother Pharmacol. 38(Suppl.):S35-S36 (1996).
Huston et al., Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli, Proc. Natl. Acad. Sci. USA85:5879-5883 (Aug. 1988).
Llovet et al., Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial,The Lancet359:1734-1739 (May 18, 2002).
Martin et al., Targeted Retroviral Infection of Tumor Cells by Receptor Cooperation,J. of Virology77(4):2753-2756 (Feb. 2003).
Molema et al., Tumor Vascular Endothelium: Barrier or Target in Tumor Directed Drug Delivery and Immunotherapy,Pharmaceutical Research14(1):2-10 (1997).
O'Brien et al., Antibody Phage Display: Methods and Protocols,E-STREAMS5(12):401 (Dec. 2002) (www.e-streams.com/es0512/es0512—2216.html).
Pastan, Targeted therapy of cancer with recombinant immunotoxins,Biochimica et Biophysica Acta1333:C1-C6 (1997).
Mechanism of Action, www.herceptin.com/herceptin/physician/j—profile/mechanism.htm Genentech, 3 pages (Aug. 6, 2003).
Mechanism of Action: Targeted Therapy Provides a Unique Profile of Efficacy, www.rituxan.com/rituxan/professional/e—product—info/mode—of—action.htm, 3 pages (Aug. 8, 2003).
Campath® Fact Sheet, www.campath.com/medpros/factsheet.html, 3 pages, (Aug. 8, 2003).
Package Insert, HUMIRA™ (adalimumab),Abbott Laboratorieswww.fda.gov/cber/label/adalabb123102LB.htm, 13 pages (Aug. 8, 2003).
Zevalin, First in Radioimmunotherapy: Mechanism of action www.zevalin.com/html/HealthcareProfessionals/ProductInformation/productInform . . . , 1 page (Aug. 8, 2003).
Hirata et al., Artificial Metastases and Decrease of Fibrinolysis in the Nude Mouse Lung After Hemithoracic Irradiation,Clin. Expl. Metastasis, 2(4), p. 311-319, (1984).
Hirata, Fate of Intravenously Injected Human Tumor Cells in the Lung of Nude Mice Following Whole-Body X-Irradiation,Invasion Metastasis, p. 61-70, (1985).
Strattonet al., Imaging Arterial Thrombosis: Comparison of Technetium-99m-Labeled Monoclonal Antifibrin Antibodies and Indium-111-Platelets,J. Nucl. Med., p. 1731-1737, (1994).
Weichselbaum et al., Gene Therapy Targeted by Radiation Preferentially Radiosensitizes Tumor Cells,Cancer Research, p. 4266-4269, (Aug. 15, 1994).

Affiliated with

Also associated with

Rating

Phage antibodies to radiation-inducible neoantigens does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phage antibodies to radiation-inducible neoantigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phage antibodies to radiation-inducible neoantigens will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3836242